Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Abstract

Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

1 - 62 . (canceled) 
     
     
         63 . A method of treating or managing glioma, comprising administering to a patient in need of such treatment or management a therapeutically effective amount of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, which has the following structure: 
       
         
           
           
               
               
           
         
         or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. 
       
     
     
         64 . The method of  claim 63 , wherein the compound is 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. 
     
     
         65 . The method of  claim 63 , wherein the compound is a pharmaceutically acceptable salt of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. 
     
     
         66 . The method of  claim 63 , wherein the glioma is glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, recurrent malignant glioma, anaplastic astrocytoma or anaplastic oligodendroglioma. 
     
     
         67 . The method of  claim 63 , wherein the cancer is relapsed or refractory. 
     
     
         68 . The method of  claim 63 , further comprising the administration of a therapeutically effective amount of one or more additional active agents. 
     
     
         69 . The method of  claim 68 , wherein the additional active agent is selected from the group consisting of temozolomide, celecoxib, etoposide, cyclophosphamide, temodar, irinotecan, carboplatin, procarbazine, temozolomide, tamoxifen, and topotecan. 
     
     
         70 . The method of  claim 63 , wherein 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or hydrate thereof is administered in an amount of from about 0.5 to about 50 mg per day. 
     
     
         71 . The method of  claim 70 , wherein the compound is administered in an amount of about 0.5 to about 5 mg per day. 
     
     
         72 . The method of  claim 70 , wherein the compound is administered in an amount of about 0.5, 1, 2, 4, 5, 10, 15, 20, 25 or 50 mg per day. 
     
     
         73 . The method of  claim 70 , wherein the compound is orally administered. 
     
     
         74 . The method of  claim 70 , wherein the compound is administered in a capsule or tablet. 
     
     
         75 . The method of  claim 74 , wherein the compound is administered in 10 mg or 25 mg of a capsule. 
     
     
         76 . The method of  claim 63 , wherein the compound is administered for 21 days followed by seven days rest in a 28 day cycle. 
     
     
         77 . The method of  claim 68 , further comprising administering radiation therapy, hormonal therapy, biological therapy or immunotherapy.